Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S, Klausz K, Albici AM, Ebinger L, Sellmer L, Teipel H, Frenzel A, Langner A, Winterberg D, Krohn S, Hust M, Schirrmann T, Dübel S, Scherließ R, Humpe A, Gramatzki M, Kellner C, Peipp M. Lutz S, et al. Among authors: peipp m. Front Immunol. 2023 Oct 27;14:1227572. doi: 10.3389/fimmu.2023.1227572. eCollection 2023. Front Immunol. 2023. PMID: 37965326 Free PMC article.
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition.
Lipinski B, Unmuth L, Arras P, Becker S, Bauer C, Toleikis L, Krah S, Doerner A, Yanakieva D, Boje AS, Klausz K, Peipp M, Siegmund V, Evers A, Kolmar H, Pekar L, Zielonka S. Lipinski B, et al. Among authors: peipp m. MAbs. 2023 Jan-Dec;15(1):2236265. doi: 10.1080/19420862.2023.2236265. MAbs. 2023. PMID: 37469014 Free PMC article.
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.
Boje AS, Pekar L, Koep K, Lipinski B, Rabinovich B, Evers A, Gehlert CL, Krohn S, Xiao Y, Krah S, Zaynagetdinov R, Toleikis L, Poetzsch S, Peipp M, Zielonka S, Klausz K. Boje AS, et al. Among authors: peipp m. MAbs. 2024 Jan-Dec;16(1):2315640. doi: 10.1080/19420862.2024.2315640. Epub 2024 Feb 19. MAbs. 2024. PMID: 38372053 Free PMC article.
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
Vogiatzi F, Heymann J, Müller K, Winterberg D, Drakul A, Rösner T, Lenk L, Heib M, Gehlert CL, Cario G, Schrappe M, Claviez A, Bornhauser B, Bourquin JP, Bomken S, Adam D, Frielitz FS, Maecker-Kolhoff B, Stanulla M, Valerius T, Peipp M, Kellner C, Schewe DM. Vogiatzi F, et al. Among authors: peipp m. Blood Adv. 2022 Aug 23;6(16):4847-4858. doi: 10.1182/bloodadvances.2022007364. Blood Adv. 2022. PMID: 35820018 Free PMC article.
132 results